BEAM
Income statement / Annual
Last year (2024), Beam Therapeutics Inc.'s total revenue was $63.52 M,
a decrease of 83.18% from the previous year.
In 2024, Beam Therapeutics Inc.'s net income was -$376.74 M.
See Beam Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$63.52 M |
$377.71 M |
$60.92 M |
$51.84 M |
$24,000.00 |
$18,000.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$437.38 M
|
$22.58 M
|
$16.44 M
|
$103.18 M
|
$5.41 M
|
$650,000.00
|
$11,000.00
|
Gross Profit |
$63.52 M
|
-$59.67 M
|
$38.34 M
|
$35.40 M
|
-$103.16 M
|
-$5.39 M
|
-$650,000.00
|
-$11,000.00
|
Gross Profit Ratio |
1
|
-0.16
|
0.63
|
0.68
|
-4298.13
|
-299.39
|
0
|
0
|
Research and Development Expenses |
$367.56 M
|
$437.38 M
|
$311.59 M
|
$387.09 M
|
$103.18 M
|
$54.62 M
|
$33.87 M
|
$5.86 M
|
General & Administrative Expenses |
$111.53 M
|
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.02 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$111.53 M
|
$116.81 M
|
$87.81 M
|
$57.22 M
|
$29.61 M
|
$20.55 M
|
$11.87 M
|
$2.02 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$71,000.00
|
-$10.04 M
|
$378,000.00
|
Operating Expenses |
$479.09 M
|
$554.19 M
|
$399.40 M
|
$444.31 M
|
$132.78 M
|
$75.17 M
|
$45.74 M
|
$7.88 M
|
Cost And Expenses |
$479.09 M
|
$554.19 M
|
$399.40 M
|
$444.31 M
|
$132.78 M
|
$75.17 M
|
$45.74 M
|
$7.88 M
|
Interest Income |
$0.00
|
$0.00
|
$15.30 M
|
$9,000.00
|
$1.57 M
|
$2.49 M
|
$292,000.00
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$15.30 M
|
$9,000.00
|
$1.57 M
|
$187,000.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$0.00
|
$20.01 M
|
$22.58 M
|
$16.44 M
|
$9.47 M
|
$5.41 M
|
$650,000.00
|
$11,000.00
|
EBITDA |
-$415.57 M |
-$156.47 M |
-$324.33 M |
-$392.47 M |
-$128.03 M |
-$71.65 M |
-$45.09 M |
-$7.99 M |
EBITDA Ratio |
-6.54
|
-0.41
|
-6.59
|
-7.99
|
-2692.71
|
-3846.44
|
0
|
0
|
Operating Income Ratio |
-6.54
|
-0.47
|
-5.56
|
-7.57
|
-5531.67
|
-4175.22
|
0
|
0
|
Total Other Income/Expenses Net |
$38.87 M
|
$45.32 M
|
$78.30 M
|
$21.83 M
|
-$61.83 M
|
-$3.17 M
|
-$71.00 M
|
-$122,000.00
|
Income Before Tax |
-$376.70 M
|
-$131.16 M
|
-$260.18 M
|
-$370.64 M
|
-$194.59 M
|
-$78.33 M
|
-$116.74 M
|
-$8.00 M
|
Income Before Tax Ratio |
-5.93
|
-0.35
|
-4.27
|
-7.15
|
-8108
|
-4351.44
|
0
|
0
|
Income Tax Expense |
$39,000.00
|
$1.37 M
|
$3.41 M
|
-$29.28 M
|
$61.83 M
|
$116,000.00
|
-$71.00 M
|
$500,000.00
|
Net Income |
-$376.74 M
|
-$132.53 M
|
-$263.59 M
|
-$341.36 M
|
-$256.42 M
|
-$78.44 M
|
-$115.26 M
|
-$8.00 M
|
Net Income Ratio |
-5.93
|
-0.35
|
-4.33
|
-6.58
|
-10684.33
|
-4357.89
|
0
|
0
|
EPS |
-4.58 |
-1.72 |
-3.76 |
-5.31 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
EPS Diluted |
-4.58 |
-1.72 |
-3.76 |
-5.31 |
-5.49 |
-1.53 |
-3.28 |
-0.62 |
Weighted Average Shares Out |
$82.31 M
|
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
Weighted Average Shares Out Diluted |
$82.31 M
|
$77.15 M
|
$70.02 M
|
$64.23 M
|
$46.73 M
|
$51.34 M
|
$35.14 M
|
$12.95 M
|
Link |
|
|
|
|
|
|
|
|